Table 1.
Characteristics of gastric cancer patients.
| ID | age | sex | tissue HER2 IHC score | Initiale TNM stagea | Grading | UICC | type Laurén | Histology adenocarcinoma | response to anti-HER2 chemotherapy |
|---|---|---|---|---|---|---|---|---|---|
| GC11 | 76 | m | 3 + pos | cT3 cN0 M1 (pul) | G2 | IIA | intestinal | moderately differentiated tubular | Responder, sec. resist |
| GC13 | 65 | f | 3 + pos | cT3 N1 Mx (hep, splenic) | G2 | IV | intestinal | moderately differentiated tubular | Responder, sec. resist |
| GC15 | 68 | m | 3 + pos | ypT3 pN1pM1 (lym, per) | G3 | IV | naa | poorly differentiated, Barrett CA | Responder, sec. resist |
| GC02 | 53 | f |
2 + pos, FISH + 6.8 |
uT3 N + M1 (bone metastasis) | G3 | IV | diffuse | poorly differentiated, signet ring cellular | Responder, SD |
| GC20 | 56 | m |
2 + pos, FISH + 6.6 |
uT3 N+ cM0 | G2 | IIB | intestinal | moderately differentiated tubular | Responder, CR |
| GC21 | 60 | m | 3 + pos | uT3 N2 M1 (pul, hep) | G2 | IV | diffuse | AC of the gastroesophageal junction | Responder, sec. resist |
| GC22 | 74 | m | 3 + pos | uTx Nx M1 (pul, hep) | G2 | IV | na | moderately differentiated, gastroesophageal type | Responder, sec. resist |
| GC05 | 72 | m | 3 + pos | uT3 μN + M0 | na | IB | mixed | poorly differentiated | No trastr, SD |
| GC07 | 59 | m | 3 + pos | uT3 μN1 μM1 (hep) | G2/3 | IV | diffuse | poorly differentiated tubular, | Responder, sec. resist |
| GC08 | 63 | m | 3 + pos | uT2 μN2 cM0 | G2 | IIIA | intestinal | well differentiated tubular | Responder, sec. resist |
| GC09 | 74 | m | 3 + pos | cTx cN1 cM (hep, per, splenic) | G1 | IV | intestinal | well differentiated tubular | Responder, sec. resist |
| GC19 | 64 | m |
2 + pos, FISH + 2.3 |
cT3 N0 M0 | G3 | IIA | intestinal | poorly differentiated tubular | Primary resistant |
| GC01 | 63 | m | neg | uT3 μN + M0 | G1 | IIB | intestinal | well differentiated tubular | No trastruzumab |
| GC03 | 66 | m | neg | uT3 μN + M0 | G2 | IIIB | na | AC of the lower third of the oesophagus (AEG) | No trastruzumab |
| GC04 | 32 | f | neg | uT3 μN + M0 | G3 | IIB | diffuse | poorly differentiated, signet ring cellular | No trastruzumab |
| GC14 | 66 | f | neg | uT3 μN + M0 | G2 | IIIB | na | moderately differentiated tubular AC of gastric antrum | No trastruzumab |
| GC16 | 58 | m | neg | uT3+ μN + M0 | G2 | IIIA | na | moderately differentiated tubular | No trastruzumab |
| GC17 | 61 | m | neg | uTx N0 M1 (hep) | G3 | IIIC | diffuse | poorly differentiated | No trastruzumab |
| GC18 | 60 | m | neg | uT3 μN + cM0 | G3 | IIB | intestinal | poorly differentiated | No trastruzumab |
| GC10 | 52 | m | na | pT3 pN1 cM0 L1 V0 Pn1 R0 | G3 | IIIA | na | poorly differentiated, distal oesophageal type | No trastruzumab |
a
na, not assessed or data missing, HER2 amplification was assessed by FISH >2.4, IHC score according to TOGA criteria, *Hep - hepatic, pul - pulmonal, per – peritoneal, f – female, m – male, AC adenocarcinoma, responder, sec resist – secondary resistant. The non-cancer group of patients includes patients with gastrointestinal symptoms without signs of malignancy.